Outset Medical, Inc. (OM)
NASDAQ: OM · IEX Real-Time Price · USD
3.610
+0.090 (2.56%)
May 17, 2024, 4:00 PM EDT - Market closed
Outset Medical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Outset Medical stock have an average target of 5.30, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 46.81% from the current stock price of 3.61.
Analyst Consensus: Buy
* Price targets were last updated on Apr 8, 2024.
Analyst Ratings
The average analyst rating for Outset Medical stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
Buy | 1 | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 3 | 3 | 3 | 3 | 3 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
BTIG | BTIG | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +66.20% | Apr 8, 2024 |
RBC Capital | RBC Capital | Buy → Hold Downgrades $14 → $6 | Buy → Hold | Downgrades | $14 → $6 | +66.20% | Jan 12, 2024 |
Morgan Stanley | Morgan Stanley | Hold Maintains $5 → $5.5 | Hold | Maintains | $5 → $5.5 | +52.35% | Dec 4, 2023 |
Morgan Stanley | Morgan Stanley | Hold Maintains $19 → $5 | Hold | Maintains | $19 → $5 | +38.50% | Nov 14, 2023 |
RBC Capital | RBC Capital | Buy Maintains $29 → $17 | Buy | Maintains | $29 → $17 | +370.91% | Oct 13, 2023 |
Financial Forecast
Revenue This Year
152.87M
from 130.38M
Increased by 17.25%
Revenue Next Year
179.14M
from 152.87M
Increased by 17.18%
EPS This Year
-2.12
from -3.48
EPS Next Year
-1.85
from -2.12
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 157.6M | 188.0M | 224.0M | 259.0M | 297.6M |
Avg | 152.9M | 179.1M | 214.2M | 251.2M | 291.9M |
Low | 142.8M | 162.4M | 200.9M | 236.3M | 277.7M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 20.9% | 22.9% | 25.0% | 20.9% | 18.4% |
Avg | 17.3% | 17.2% | 19.6% | 17.3% | 16.2% |
Low | 9.5% | 6.2% | 12.1% | 10.3% | 10.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.05 | -1.73 | -1.23 | -1.09 | -0.83 |
Avg | -2.12 | -1.85 | -1.42 | -1.18 | -0.81 |
Low | -2.14 | -1.95 | -1.52 | -1.23 | -0.77 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.